Actionable news
0
All posts from Actionable news
Actionable news in RDHL: Redhill Biopharma Ltd.,

Redhill Biopharma To Present At The Jefferies Autumn 2015 Global Healthcare Conference EXHIBIT 99.1

The following excerpt is from the company's SEC filing.

RedHill Biopharma to Present at the Jefferies Autumn 2015 Global Healthcare Conference

TEL-AVIV, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced, that Dror Ben-Asher, RedHill's Chief Executive Officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference, on Wednesday, November 18, at 2:40 p.m. GMT, at The May Fair Hotel in London.

A live audio and slide webcast of the presentation will be available on the Company's website at:http://ir.redhillbio.com/events.cfm. A copy of the presentation is available on the Company's website and a replay of the webcast will be available on the Company's website for a period of 30 days.

About RedHill Biopharma Ltd.:

RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is an emerging Israeli biopharmaceutical company primarily focused on the development of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. RedHill's current pipeline of proprietary products includes: (i)

RHB-105

an oral combination therapy for the treatment of

Helicobacter pylori

infection, with successful top-line results from a first Phase III study; (ii)

RHB-104

an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study; (iii)

BEKINDA

(RHB-102)

a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis; (iv)

RHB-106

an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v)

YELIVA

(ABC294640)

an orally-administered first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications with a Phase I/II study initiated...


More